About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Neurodegenerative Disease Market Size & Demand By 2030
Neurodegenerative Disease Market
Select Regional / Country Report
Global Asia Pacific Europe North America Middle East And Africa LAMEA

Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy (SMA) , Other Indication Types), By Drug Type (N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, SSRIs, Other Drug Types) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRHI1582DR
Last Updated : October 17, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Neurodegenerative Disease Market Introduction
    2. By Indication Type
      1. Introduction
        1. Indication Type By Value
      2. Parkinson's Disease
        1. By Value
      3. Alzheimer's Disease
        1. By Value
      4. Multiple Sclerosis
        1. By Value
      5. Huntington Disease
        1. By Value
      6. Amyotrophic Lateral Sclerosis
        1. By Value
      7. Spinal Muscular Atrophy (SMA) 
        1. By Value
      8. Other Indication Types
        1. By Value
    3. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. N-methyl-D-aspartate Receptor antagonists
        1. By Value
      3. Cholinesterase Inhibitors
        1. By Value
      4. Dopamine Agonists
        1. By Value
      5. Immunomodulatory Drugs
        1. By Value
      6. Acetylcholinesterase (AChE) Inhibitors
        1. By Value
      7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
        1. By Value
      8. Catechol-O-Methyltransferase (COMT) Inhibitor
        1. By Value
      9. SSRIs
        1. By Value
      10. Other Drug Types
        1. By Value
    1. Introduction
    2. By Indication Type
      1. Introduction
        1. Indication Type By Value
      2. Parkinson's Disease
        1. By Value
      3. Alzheimer's Disease
        1. By Value
      4. Multiple Sclerosis
        1. By Value
      5. Huntington Disease
        1. By Value
      6. Amyotrophic Lateral Sclerosis
        1. By Value
      7. Spinal Muscular Atrophy (SMA) 
        1. By Value
      8. Other Indication Types
        1. By Value
    3. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. N-methyl-D-aspartate Receptor antagonists
        1. By Value
      3. Cholinesterase Inhibitors
        1. By Value
      4. Dopamine Agonists
        1. By Value
      5. Immunomodulatory Drugs
        1. By Value
      6. Acetylcholinesterase (AChE) Inhibitors
        1. By Value
      7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
        1. By Value
      8. Catechol-O-Methyltransferase (COMT) Inhibitor
        1. By Value
      9. SSRIs
        1. By Value
      10. Other Drug Types
        1. By Value
    4. U.S.
      1. By Indication Type
        1. Introduction
          1. Indication Type By Value
        2. Parkinson's Disease
          1. By Value
        3. Alzheimer's Disease
          1. By Value
        4. Multiple Sclerosis
          1. By Value
        5. Huntington Disease
          1. By Value
        6. Amyotrophic Lateral Sclerosis
          1. By Value
        7. Spinal Muscular Atrophy (SMA) 
          1. By Value
        8. Other Indication Types
          1. By Value
      2. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. N-methyl-D-aspartate Receptor antagonists
          1. By Value
        3. Cholinesterase Inhibitors
          1. By Value
        4. Dopamine Agonists
          1. By Value
        5. Immunomodulatory Drugs
          1. By Value
        6. Acetylcholinesterase (AChE) Inhibitors
          1. By Value
        7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
          1. By Value
        8. Catechol-O-Methyltransferase (COMT) Inhibitor
          1. By Value
        9. SSRIs
          1. By Value
        10. Other Drug Types
          1. By Value
    5. Canada
    1. Introduction
    2. By Indication Type
      1. Introduction
        1. Indication Type By Value
      2. Parkinson's Disease
        1. By Value
      3. Alzheimer's Disease
        1. By Value
      4. Multiple Sclerosis
        1. By Value
      5. Huntington Disease
        1. By Value
      6. Amyotrophic Lateral Sclerosis
        1. By Value
      7. Spinal Muscular Atrophy (SMA) 
        1. By Value
      8. Other Indication Types
        1. By Value
    3. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. N-methyl-D-aspartate Receptor antagonists
        1. By Value
      3. Cholinesterase Inhibitors
        1. By Value
      4. Dopamine Agonists
        1. By Value
      5. Immunomodulatory Drugs
        1. By Value
      6. Acetylcholinesterase (AChE) Inhibitors
        1. By Value
      7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
        1. By Value
      8. Catechol-O-Methyltransferase (COMT) Inhibitor
        1. By Value
      9. SSRIs
        1. By Value
      10. Other Drug Types
        1. By Value
    4. U.K.
      1. By Indication Type
        1. Introduction
          1. Indication Type By Value
        2. Parkinson's Disease
          1. By Value
        3. Alzheimer's Disease
          1. By Value
        4. Multiple Sclerosis
          1. By Value
        5. Huntington Disease
          1. By Value
        6. Amyotrophic Lateral Sclerosis
          1. By Value
        7. Spinal Muscular Atrophy (SMA) 
          1. By Value
        8. Other Indication Types
          1. By Value
      2. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. N-methyl-D-aspartate Receptor antagonists
          1. By Value
        3. Cholinesterase Inhibitors
          1. By Value
        4. Dopamine Agonists
          1. By Value
        5. Immunomodulatory Drugs
          1. By Value
        6. Acetylcholinesterase (AChE) Inhibitors
          1. By Value
        7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
          1. By Value
        8. Catechol-O-Methyltransferase (COMT) Inhibitor
          1. By Value
        9. SSRIs
          1. By Value
        10. Other Drug Types
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Indication Type
      1. Introduction
        1. Indication Type By Value
      2. Parkinson's Disease
        1. By Value
      3. Alzheimer's Disease
        1. By Value
      4. Multiple Sclerosis
        1. By Value
      5. Huntington Disease
        1. By Value
      6. Amyotrophic Lateral Sclerosis
        1. By Value
      7. Spinal Muscular Atrophy (SMA) 
        1. By Value
      8. Other Indication Types
        1. By Value
    3. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. N-methyl-D-aspartate Receptor antagonists
        1. By Value
      3. Cholinesterase Inhibitors
        1. By Value
      4. Dopamine Agonists
        1. By Value
      5. Immunomodulatory Drugs
        1. By Value
      6. Acetylcholinesterase (AChE) Inhibitors
        1. By Value
      7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
        1. By Value
      8. Catechol-O-Methyltransferase (COMT) Inhibitor
        1. By Value
      9. SSRIs
        1. By Value
      10. Other Drug Types
        1. By Value
    4. China
      1. By Indication Type
        1. Introduction
          1. Indication Type By Value
        2. Parkinson's Disease
          1. By Value
        3. Alzheimer's Disease
          1. By Value
        4. Multiple Sclerosis
          1. By Value
        5. Huntington Disease
          1. By Value
        6. Amyotrophic Lateral Sclerosis
          1. By Value
        7. Spinal Muscular Atrophy (SMA) 
          1. By Value
        8. Other Indication Types
          1. By Value
      2. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. N-methyl-D-aspartate Receptor antagonists
          1. By Value
        3. Cholinesterase Inhibitors
          1. By Value
        4. Dopamine Agonists
          1. By Value
        5. Immunomodulatory Drugs
          1. By Value
        6. Acetylcholinesterase (AChE) Inhibitors
          1. By Value
        7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
          1. By Value
        8. Catechol-O-Methyltransferase (COMT) Inhibitor
          1. By Value
        9. SSRIs
          1. By Value
        10. Other Drug Types
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Indication Type
      1. Introduction
        1. Indication Type By Value
      2. Parkinson's Disease
        1. By Value
      3. Alzheimer's Disease
        1. By Value
      4. Multiple Sclerosis
        1. By Value
      5. Huntington Disease
        1. By Value
      6. Amyotrophic Lateral Sclerosis
        1. By Value
      7. Spinal Muscular Atrophy (SMA) 
        1. By Value
      8. Other Indication Types
        1. By Value
    3. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. N-methyl-D-aspartate Receptor antagonists
        1. By Value
      3. Cholinesterase Inhibitors
        1. By Value
      4. Dopamine Agonists
        1. By Value
      5. Immunomodulatory Drugs
        1. By Value
      6. Acetylcholinesterase (AChE) Inhibitors
        1. By Value
      7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
        1. By Value
      8. Catechol-O-Methyltransferase (COMT) Inhibitor
        1. By Value
      9. SSRIs
        1. By Value
      10. Other Drug Types
        1. By Value
    4. UAE
      1. By Indication Type
        1. Introduction
          1. Indication Type By Value
        2. Parkinson's Disease
          1. By Value
        3. Alzheimer's Disease
          1. By Value
        4. Multiple Sclerosis
          1. By Value
        5. Huntington Disease
          1. By Value
        6. Amyotrophic Lateral Sclerosis
          1. By Value
        7. Spinal Muscular Atrophy (SMA) 
          1. By Value
        8. Other Indication Types
          1. By Value
      2. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. N-methyl-D-aspartate Receptor antagonists
          1. By Value
        3. Cholinesterase Inhibitors
          1. By Value
        4. Dopamine Agonists
          1. By Value
        5. Immunomodulatory Drugs
          1. By Value
        6. Acetylcholinesterase (AChE) Inhibitors
          1. By Value
        7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
          1. By Value
        8. Catechol-O-Methyltransferase (COMT) Inhibitor
          1. By Value
        9. SSRIs
          1. By Value
        10. Other Drug Types
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Indication Type
      1. Introduction
        1. Indication Type By Value
      2. Parkinson's Disease
        1. By Value
      3. Alzheimer's Disease
        1. By Value
      4. Multiple Sclerosis
        1. By Value
      5. Huntington Disease
        1. By Value
      6. Amyotrophic Lateral Sclerosis
        1. By Value
      7. Spinal Muscular Atrophy (SMA) 
        1. By Value
      8. Other Indication Types
        1. By Value
    3. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. N-methyl-D-aspartate Receptor antagonists
        1. By Value
      3. Cholinesterase Inhibitors
        1. By Value
      4. Dopamine Agonists
        1. By Value
      5. Immunomodulatory Drugs
        1. By Value
      6. Acetylcholinesterase (AChE) Inhibitors
        1. By Value
      7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
        1. By Value
      8. Catechol-O-Methyltransferase (COMT) Inhibitor
        1. By Value
      9. SSRIs
        1. By Value
      10. Other Drug Types
        1. By Value
    4. Brazil
      1. By Indication Type
        1. Introduction
          1. Indication Type By Value
        2. Parkinson's Disease
          1. By Value
        3. Alzheimer's Disease
          1. By Value
        4. Multiple Sclerosis
          1. By Value
        5. Huntington Disease
          1. By Value
        6. Amyotrophic Lateral Sclerosis
          1. By Value
        7. Spinal Muscular Atrophy (SMA) 
          1. By Value
        8. Other Indication Types
          1. By Value
      2. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. N-methyl-D-aspartate Receptor antagonists
          1. By Value
        3. Cholinesterase Inhibitors
          1. By Value
        4. Dopamine Agonists
          1. By Value
        5. Immunomodulatory Drugs
          1. By Value
        6. Acetylcholinesterase (AChE) Inhibitors
          1. By Value
        7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
          1. By Value
        8. Catechol-O-Methyltransferase (COMT) Inhibitor
          1. By Value
        9. SSRIs
          1. By Value
        10. Other Drug Types
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Neurodegenerative Disease Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Amneal Pharmaceuticals Inc.
    2. Boehringer Ingelheim International GmbHF
    3. Hoffmann-La Roche
    4. Merck & Co. Inc.
    5. Pfizer Inc.
    6. Teva Pharmaceuticals Ltd
    7. UCB SA
    8. Biogen Inc
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Regenerative Medicine Market Size The global regenerative medicine market size is estimated to be worth USD 19.80 billion in 2024 and is projected to reach from USD 24.88 billion in 2025 to USD 148.42 billion by 2033, growing at
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.